Equity Overview
Price & Market Data
Price: $0.862
Daily Change: +$0.0021 / 0.24%
Range: $0.84 - $0.886
Market Cap: $3,851,753
Volume: 7,261
Performance Metrics
1 Week: -2.07%
1 Month: -16.99%
3 Months: -45.01%
6 Months: -81.24%
1 Year: -53.69%
YTD: -51.65%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.